From the editor

Friday, December 23, 2016 Published in Impact October 2012 Written by Cepheid

Welcome to the fourth issue of IMPACT, the quarterly magazine published by Cepheid’s Systems & Solutions Group.

In this issue, Dr. Al Story and Dr. Rob Shorten share their particularly innovative and effective program for diagnosing tuberculosis in London. These two doctors are using an innovative Mobile X-Ray Unit (MXU) to improve TB diagnosis for hard-to-reach patients. This is the first example of a molecular diagnostic test being used in a mobile unit for near-patient testing anywhere in Europe.

Innovative Mobile X-Ray Unit and Xpert® MTB/RIF

Friday, December 23, 2016 Published in Impact October 2012 Written by Dr. Al Story, Clinical Lead for Find and Treat & Dr. Rob Shorten, Royal Free Hospital and University College London

The mobile x-ray unit (MXU) has been operating in London since 2005. It is staffed by TB nurse specialists, reporting radiographers, social workers and outreach workers. Its role is to identify hard-to-reach patients with suspected TB using digital chest radiograph. These patients, including individuals who are homeless or have substance abuse issues, are then linked into local healthcare provision via A&E or community TB programmes.

Improving Patient Safety

Friday, December 23, 2016 Published in Impact October 2012 Written by Jorge P. Parada, MD, MPH, FACP, FIDSA, Prof. of Medicine, Stritch School of Medicine Loyola University, Chicago

Loyola Meets the C. difficile Challenge

As noted in the June 2012 issue of Impact, there is a great deal of pressure on hospitals to be more accountable, and the pressure is only growing. Accountability reporting will impact hospital finances on multiple fronts: from reimbursement changes to patient hospital selection for elective procedures.

Needless to say, Healthcare associated infections (HAIs) are a key part of the accountability metrics required and soon-to-be required. In our first article, we explored Loyola University Hospital’s implementation of rapid, highly sensitive universal screening to successfully combat methicillin-resistant Staphylococcus aureus (MRSA).(1) In this article, we’ll look at how the hospital addressed another common and increasingly troublesome HAI: Clostridium difficile (C. difficile).

Inside Cepheid Innovation

Friday, December 23, 2016 Published in Impact October 2012 Written by Ron Chang, Cepheid Fellow and Doug Dority, Cepheid Fellow

Architecting Ease of Use

Ron and Doug first met when 12-year-old Ron was walking to a friend’s home one day and saw Doug taking apart a bike. The two have been building things together ever since. In this issue of IMPACT we sit down with Cepheid Fellows Doug Dority and Ron Chang as they discuss how they work together to help deliver unprecedented speed and ease-of-use with Cepheid’s molecular testing technology.

Just the Facts

Friday, December 23, 2016 Published in Impact October 2012 Written by Cepheid

FACT.

A USA Today investigation for an August 2012 cover story asserted that rates of death and illness from C. difficile infection are much higher than national reports have shown because the 14,000 deaths that the CDC reported in their most recent report are based on information from death certificates — which often don’t list C. difficile when patients die from complications of the infection, such as kidney failure.*

From the Editor

Friday, December 23, 2016 Published in On-Demand Spring 2013 Written by David Persing M.D., Ph.D., Chief Medical and Technology Officer, Cepheid

In this issue of On Demand, Dr. Ellen Jo Baron provides a comprehensive summary of the public health challenge posed by Group B Streptococcus (GBS) and the “Test and Treat” strategies that have been highly effective in interrupting transmission of this pathogen. Cepheid is pleased to be able to offer comprehensive GBS testing options for the antepartum and intrapartum setting; our most recently cleared GBS testing option, Xpert® GBS LB, combines ease of use with superior sensitivity. We think you will find this issue to be highly informative.

Group B Streptococcal Neonatal Disease: Mission Accomplished??

Friday, December 23, 2016 Published in On-Demand Spring 2013 Written by Written by Ellen Jo Baron Ph.D., D(ABMM) Prof. Emerita, Stanford University Director of Medical Affairs, Cepheid

Testing pregnant women for their group B streptococcal (GBS) colonization status was not a widespread practice in U.S. clinical microbiology laboratories, even after the Centers for Disease Control and Prevention published their initial draft guidelines in 1994 and recommendations in 1996.12 Since seminal publications appeared in the 1970’s, it was known that early onset GBS disease (EOGBSD) was acquired by the neonate either right before delivery or as it passed through the colonized birth canal.6 As recently as 1972, 2 infants per 1000 live births were affected and there were 12,000 cases per year in the U.S. The fatality rate among infected infants was 50%. In fact, when I first arrived in Palo Alto to direct the clinical microbiology laboratories at Stanford in 1997, the Department of Obstetrics and Gynecology was still relying on risk-based prophylaxis for women arriving in labor rather than antenatal cultures, in contrast to the community laboratories for which I had been consulting in southern California.

Cost-effective Management of Clostridium difficile Infection—the Humanitas Experience

Friday, December 23, 2016 Published in January 2014 Written by Dr. Erminia Casari is Director at the Microbiology Laboratory of Humanitas Hospital in Milan, Italy and Professor of Microbiology at the Specializing School of Microbiology and Virology at University of Pavia

Clostridium difficile infection (CDI) is increasingly recognized as one of the most important healthcare associated infections throughout Europe, Canada and the United States.[1] The increasing incidence and severity has been attributed to the emergence of the hypervirulent strains PCR ribotypes 027 and 078 and the prevalence of CDI has risen from 3% to 13% [2, 3]. With the increasing infection rates from C. difficile, many recent studies have focused on the economic burden imposed by the management of CDI – notably, extended hospitalization, laboratory costs, and medical costs.[4]

Industry Q&A - Inside Cepheid Innovation: Women’s Health Portfolio

Friday, December 23, 2016 Published in January 2014 Written by Dr. David Persing, Chief Medical and Technology Officer, and Dr. Fred Weir, Director of Research and Development

Dr. David Persing and Dr. Fred Weir discuss the development of Xpert CT/NG, GBS LB and why these recently introduced tests are an important step in Cepheid’s plans for a complete line of Women’s Health diagnostic tests

From the Editor

Friday, December 23, 2016 Published in Impact July 2012 Written by Cepheid

Welcome to the third issue of IMPACT, a quarterly magazine published by Cepheid’s Systems & Solutions Group.